Biomaterials, Год журнала: 2025, Номер 322, С. 123386 - 123386
Опубликована: Май 3, 2025
Язык: Английский
European Journal of Pharmacology, Год журнала: 2025, Номер unknown, С. 177351 - 177351
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
0
BMC Surgery, Год журнала: 2025, Номер 25(1)
Опубликована: Фев. 18, 2025
To analyze the impact of preoperative inflammatory markers and tumor on lymphatic metastasis postoperative complications in colorectal cancer patients, explore their predictive value for these outcomes. Furthermore, based marker indicators with significant effects, models risk incidence will be constructed. This study retrospectively analyzed clinical data CRC patients who underwent surgical treatment at Shanxi Bethune Hospital between January 2021 June 2024. Preoperative were compared lymph node-positive node-negative groups. Variables selected using Lasso regression, independent factors influencing node identified through multivariate logistic regression analysis. Based results, a Nomogram prediction model was constructed, its accuracy evaluated calibration curve. The discriminatory ability assessed ROC curve, applicability DCA Similarly, predicting complications, Pearson correlation analysis used to examine relationships markers, complications. curves employed calculate AUC optimal cutoff values each marker. Kaplan-Meier (KM) DFS. Independent univariate analyses, constructed validated. A total 196 included study. NLR, PLR, FAR, CEA, CA199, CA724 levels significantly elevated group (P < 0.05). smoking history, as non-zero coefficient variables. Multivariate further confirmed history (HR = 4.20), NLR 2.52), FAR 1.18), 1.32) predictors results showed high accuracy, curve 0.880, indicating excellent ability. decision demonstrated good applicability. In complication prediction, revealed positive rates 0.05), coefficients 0.24, 0.34, 0.16, 0.19, respectively, PLR showing strongest correlation. that AUCs LMR, CAR 0.633, 0.675, 0.467, 0.580, 0.559, 4.29, 261.71, 3.39, 18.20, 11.26, respectively. 0.567, 0.612, 0.609, 11.87, 10.27, 6.85. KM higher CAR, associated poorer Univariate 1.53) 1.11) indicated 0.729, demonstrating ability, have occurrence certain developed this provide reference personalized diagnosis treatment, but practical application needs validated large-scale studies.
Язык: Английский
Процитировано
0
CytoJournal, Год журнала: 2025, Номер 22, С. 29 - 29
Опубликована: Март 6, 2025
Colorectal cancer (CRC) presents significant treatment challenges, including immune evasion and tumor microenvironment (TME) suppression. Chimeric antigen receptor (CAR) T-cell therapy has shown promise in hematologic malignancies, but its effectiveness against solid tumors is hampered by the detrimental effects of TME. This article aims to explore potential bispecific CAR T cells targeting programmed death-ligand 1 (PD-L1) cancer-associated fibroblasts (CAFs) CRC treatment. Dual-targeted CAR-T PD-L1 CAF were engineered using GV400 lentiviral vector. Programmed death-1 (PD-1)/nanobody (Nb) fibroblast activation protein (FAP)/Nb-encoding vectors generated, produced through a three-plasmid system 293T cells. Human peripheral blood mononuclear (PBMCs) separated, transduced with these vectors, then expanded. Functional characterization was performed enzyme-linked immunosorbent assay (ELISA), Western blot analysis, flow cytometry, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assays, cell counting kit-8 (CCK-8) assay. Migration invasion assays conducted Transwell chambers assess ability FAP-PD-1/Nb migrate toward invade extracellular matrix. We developed dual-targeted incorporating Nbs, which continuously secreted PD-1/Nb. confirmed PD-1/Nb expression cells, no untreated (UTD) group (P < 0.01). Flow cytometry showed significantly higher cluster differentiation (CD)25 CD69 upon stimulation FAP-positive target compared other groups TUNEL, CCK-8 revealed that exhibited superior cytotoxicity proliferation inhibition HCT116 ELISA demonstrated increased interferon-gamma necrosis factor-alpha levels reduced interleukin-10 0.01), suggesting enhanced cytokine modulation antitumor immunity. Compared single-target UTD, notably Matrigel penetration Safety tests minimal normal PBMCs, indicating favorable safety. study successfully their activity immunomodulatory on novel therapeutic strategy established technology for CRC.
Язык: Английский
Процитировано
0
Journal of Immunology Research, Год журнала: 2025, Номер 2025(1)
Опубликована: Янв. 1, 2025
Colorectal cancer (CRC) stands as one of the tumors with globally high incidence and mortality rates. In recent years, researchers have extensively explored role tumor immune microenvironment (TME) in CRC, highlighting crucial influence cell populations driving progression shaping therapeutic outcomes. The TME encompasses an array cellular noncellular constituents, spanning cells, myeloid tumor-associated fibroblasts, among others. However, composition within is highly dynamic, evolving throughout different stages progression. These shifts subpopulation proportions lead to a gradual transition response, shifting from early antitumor growth late-stage environment that supports survival. Therefore, it further investigate understand complex interactions various TME. this review, we explore key components varying origins, subpopulations shared elements CRC TME, examining their interconnections critical considerations for developing personalized precise immunotherapy strategies.
Язык: Английский
Процитировано
0
The Journal of Immunology, Год журнала: 2025, Номер unknown
Опубликована: Апрель 15, 2025
Abstract Inducible Co-Stimulator (ICOS), as a T-cell–specific costimulatory receptor that enhances T-cell responses to foreign antigens, plays crucial role in cancer immunity. However, its MSS/pMMR colorectal (CRC) remains unclear. In this study, we demonstrated ICOS expression decreases the tumor stages advance and high is associated with favorable prognosis CRC. Mechanistically, promoted secretion of IFN-γ, TNF-α, IL-12 CD4+ T cells through Akt/STAT1/T-bet axis, leading inhibition MSS/pMMR-CRC-cell proliferation. Importantly, ICOS+ enhanced anti-PD-1 therapy conclusion, study revealed mediates antitumor immunity by promoting cancer-suppressive cytokines. It also suggests activation serves potential therapeutic strategy for
Язык: Английский
Процитировано
0
Biomaterials, Год журнала: 2025, Номер 322, С. 123386 - 123386
Опубликована: Май 3, 2025
Язык: Английский
Процитировано
0